Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Fusion Pharmaceuticals stock price, quote, forecast and news

FUSN
CA36118A1003

Price

21.55
Today +/-
+0
Today %
+0 %
P

Fusion Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Fusion Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Fusion Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Fusion Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Fusion Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Fusion Pharmaceuticals Stock Price History

DateFusion Pharmaceuticals Price
6/4/202421.55 undefined
6/3/202421.55 undefined

Fusion Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Fusion Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Fusion Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Fusion Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Fusion Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Fusion Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Fusion Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Fusion Pharmaceuticals’s growth potential.

Fusion Pharmaceuticals Revenue, EBIT and net profit per share

DateFusion Pharmaceuticals RevenueFusion Pharmaceuticals EBITFusion Pharmaceuticals Net Income
2029e335.49 M undefined0 undefined101.51 M undefined
2028e51.02 M undefined-133.68 M undefined-91.32 M undefined
2027e582,277.2 undefined-185.32 M undefined-145.76 M undefined
2026e8.91 M undefined-152.91 M undefined-148.07 M undefined
2025e409,315.82 undefined-142.92 M undefined-145.63 M undefined
2024e394,740 undefined-128.22 M undefined-125.61 M undefined
20232.07 M undefined-99.23 M undefined-94.9 M undefined
20221.46 M undefined-88.03 M undefined-87.61 M undefined
20211.44 M undefined-82.02 M undefined-81.05 M undefined
20200 undefined-37.94 M undefined-79.72 M undefined
20190 undefined-18.22 M undefined-16.19 M undefined
20180 undefined-10.1 M undefined-11.65 M undefined
20170 undefined-6.99 M undefined-6.26 M undefined

Fusion Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
0000112008051335
------100.00-----556.86
-------------
0000000000000
-6-10-18-37-82-88-99-128-142-152-185-1330
-----8,200.00-8,800.00-4,950.00---1,900.00--260.78-
-6-11-16-79-81-87-94-125-145-148-145-91101
-83.3345.45393.752.537.418.0532.9816.002.07-2.03-37.24-210.99
41.6641.6641.6641.7342.643.7565.61000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Fusion Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Fusion Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
28.865.3222.4200.8170.9233.61
0004001007
0002.21.65.47
000000
10.858.46.44.31
29.866.1227.4211.8179243.4
1.11.329.510.323.9
0077.12015.813.74
000000
000000
000000
0.11.63.511.1144.81
1.22.982.640.640.142.44
3169310252.4219.1285.84
           
32.471.60000
0.71.3407.7425.8444.6599
-18.6-34.8-113.2-194.3-281.9-376.76
000-100-500237
000000
14.538.1294.5231.4162.2222.48
0.30.83.42.22.71.86
1.23.24.78.811.413.94
0.10.23.81.510.42
000000
000000
1.64.211.912.515.116.22
05.70034.234.78
000000
0.20.34.38.37.512.36
0.264.38.341.747.14
1.810.216.220.856.863.36
16.348.3310.7252.2219285.84
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Fusion Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Fusion Pharmaceuticals's financial health and stability.

Assets

Fusion Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Fusion Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Fusion Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Fusion Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-6-11-16-78-81-87-94
0000001,000
00000-30
0035-143-1
02046282324
0000014
0000311
-6-9-13-29-75-73-81
0-10-1-1-2-3
0-10-2103723-42
000-2093925-38
0000000
00000340
27185227006146
271852265040142
----4.00---4.00
0000000
2073825-37-917
-6.23-10.99-14.15-30.89-77.23-75.42-85.69
0000000

Fusion Pharmaceuticals stock margins

The Fusion Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fusion Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fusion Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Fusion Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Fusion Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Fusion Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Fusion Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Fusion Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Fusion Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Fusion Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Fusion Pharmaceuticals Margin History

Fusion Pharmaceuticals Gross marginFusion Pharmaceuticals Profit marginFusion Pharmaceuticals EBIT marginFusion Pharmaceuticals Profit margin
2029e0 %0 %30.26 %
2028e0 %-262.02 %-178.98 %
2027e0 %-31,826.22 %-25,032.55 %
2026e0 %-1,716.72 %-1,662.43 %
2025e0 %-34,917.85 %-35,580.04 %
2024e0 %-32,483.08 %-31,821.23 %
20230 %-4,798.45 %-4,588.83 %
20220 %-6,029.45 %-6,000.68 %
20210 %-5,695.83 %-5,628.47 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Fusion Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Fusion Pharmaceuticals earnings per share therefore indicates how much revenue Fusion Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fusion Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fusion Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fusion Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fusion Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Fusion Pharmaceuticals Revenue, EBIT and net profit per share

DateFusion Pharmaceuticals Sales per ShareFusion Pharmaceuticals EBIT per shareFusion Pharmaceuticals Earnings per Share
2029e3.94 undefined0 undefined1.19 undefined
2028e0.6 undefined0 undefined-1.07 undefined
2027e0.01 undefined0 undefined-1.71 undefined
2026e0.1 undefined0 undefined-1.74 undefined
2025e0 undefined0 undefined-1.71 undefined
2024e0 undefined0 undefined-1.48 undefined
20230.03 undefined-1.51 undefined-1.45 undefined
20220.03 undefined-2.01 undefined-2 undefined
20210.03 undefined-1.93 undefined-1.9 undefined
20200 undefined-0.91 undefined-1.91 undefined
20190 undefined-0.44 undefined-0.39 undefined
20180 undefined-0.24 undefined-0.28 undefined
20170 undefined-0.17 undefined-0.15 undefined

Fusion Pharmaceuticals business model

Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development of innovative cancer therapies. The company was founded in Canada in 2014 and has since pursued a unique approach to cancer treatment: targeted radiation therapy. Fusion Pharmaceuticals' business model is based on providing cancer patients with an effective and gentle alternative to conventional treatment methods. The company utilizes a novel technology that allows radioisotopes to be specifically targeted to cancer cells. This enables radiation to be applied directly to the affected areas without damaging healthy tissue. Fusion Pharmaceuticals specializes in the development of therapies for solid tumors. The company collaborates with various partners to offer a wide range of treatment options. The key products currently include: - FP-1001: This product is currently in Phase 1 clinical trials and is intended for the treatment of patients with solid tumors. FP-1001 combines a specific antibody molecule with the radioactive isotope Actinium-225 to selectively destroy cancer cells. - FP-2000: This product is currently in the preclinical phase and aims to provide an effective treatment for pancreatic cancer. FP-2000 combines a specific antibody molecule with the radioactive isotope Lutetium-177 and has the potential to improve the survival rate of patients with this severe disease. - FP-3000: This product is also in the preclinical phase and is intended for the treatment of prostate cancer. FP-3000 combines a specific antibody molecule with the radioactive isotope Copper-67 and has the potential to offer an effective alternative to conventional treatments such as chemotherapy. Fusion Pharmaceuticals has rapidly gained importance in recent years and has attracted numerous prestigious investors. These include Canadian investment firm OrbiMed Advisors LLC and renowned US biotechnology company Johnson & Johnson. The company has also received several awards, including the Innovation Award from the Canadian government in 2019. For the future, Fusion Pharmaceuticals plans to further expand its development pipeline and create new therapies for a wide range of cancer diseases. The company aims to provide cancer patients worldwide with new hope and an effective alternative to conventional treatment methods. Fusion Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Fusion Pharmaceuticals SWOT Analysis

Strengths

Fusion Pharmaceuticals Inc is a promising biotechnology company with several notable strengths.

  • Strong scientific expertise: The company is backed by a highly skilled team of scientists, researchers, and industry experts who possess extensive knowledge in the field of targeted alpha therapeutics.
  • Advanced technology platform: Fusion Pharmaceuticals utilizes cutting-edge technology and innovative radiopharmaceutical techniques to design and develop highly precise cancer treatments.
  • Collaborative partnerships: The company has established strategic collaborations with renowned academic institutions and pharmaceutical companies, allowing them to leverage shared expertise and resources for research and development.
  • Promising pipeline: Fusion Pharmaceuticals boasts a robust pipeline of product candidates, targeting various cancer indications, which demonstrates the potential for significant future growth and revenue.
  • Strong intellectual property portfolio: The company holds a valuable portfolio of patents and intellectual property rights, providing a competitive advantage and protection for their innovative technologies and products.

Weaknesses

While Fusion Pharmaceuticals has numerous strengths, it also faces certain weaknesses that should be taken into consideration.

  • Dependency on successful clinical trials: The company's success heavily relies on the positive outcomes of ongoing and future clinical trials. Any setbacks or failures in these trials could have a significant impact on their progress and reputation.
  • Relatively early-stage development: Fusion Pharmaceuticals is still in the early stages of development, which means there is a higher level of uncertainty and risk associated with their product candidates and overall business operations.
  • Limited market presence: Compared to well-established pharmaceutical companies, Fusion Pharmaceuticals lacks a strong market presence and brand recognition, making it challenging to compete and capture market share.

Opportunities

Despite the weaknesses, Fusion Pharmaceuticals also has several opportunities that can contribute to their future success.

  • Expanding radiopharmaceutical market: The global radiopharmaceutical market is expected to experience significant growth in the coming years, presenting Fusion Pharmaceuticals with opportunities to capitalize on this expanding market and increase their market share.
  • Increasing demand for targeted cancer therapies: With the growing focus on personalized medicine and targeted cancer treatments, Fusion Pharmaceuticals is well-positioned to benefit from the increasing demand for their highly precise and effective therapies.
  • New strategic partnerships: The company can explore and establish additional collaborations with industry partners to expand their research capabilities, gain access to new technologies, or strengthen their market presence through joint ventures and licensing agreements.

Threats

As with any business, Fusion Pharmaceuticals faces certain external threats that could impact their operations and growth prospects.

  • Stringent regulatory environment: The biotechnology and pharmaceutical industry face complex and ever-evolving regulatory requirements, which could pose challenges and delays in obtaining necessary approvals for their products.
  • Competition from established players: Fusion Pharmaceuticals competes with well-established pharmaceutical companies that have substantial resources and established market presence. This intense competition could hinder their ability to gain market share.
  • Funding limitations: Developing innovative therapies and conducting clinical trials require significant financial resources. If Fusion Pharmaceuticals faces difficulties in securing adequate funding, it could impact their research and development activities.

Fusion Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Fusion Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Fusion Pharmaceuticals shares outstanding

The number of shares was Fusion Pharmaceuticals in 2023 — This indicates how many shares 65.612 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Fusion Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Fusion Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Fusion Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Fusion Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Fusion Pharmaceuticals.

Fusion Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2024-0.38 -0.4  (-5.51 %)2024 Q1
12/31/2023-0.34 -0.39  (-13.31 %)2023 Q4
9/30/2023-0.41 -0.25  (38.59 %)2023 Q3
6/30/2023-0.4 -0.38  (4.21 %)2023 Q2
3/31/2023-0.32 -0.45  (-38.93 %)2023 Q1
12/31/2022-0.57 -0.55  (3.02 %)2022 Q4
9/30/2022-0.51 -0.55  (-7.84 %)2022 Q3
6/30/2022-0.54 -0.44  (19 %)2022 Q2
3/31/2022-0.49 -0.46  (6.05 %)2022 Q1
12/31/2021-0.48 -0.4  (15.97 %)2021 Q4
1
2

Fusion Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
7.64205 % Avidity Partners Management LP6,500,328-324,12212/31/2023
7.52528 % Deerfield Management Company, L.P.6,401,0003,578,00012/31/2023
6.24535 % Fidelity Management & Research Company LLC5,312,2971,135,44612/31/2023
5.56924 % Perceptive Advisors LLC4,737,1941,985,7991/9/2024
4.51529 % HealthCap AB3,840,70233,4553/18/2024
4.31521 % Johnson & Johnson Innovation-JJDC, Inc.3,670,516012/31/2023
3.82903 % Varian Medical Systems, Inc.3,256,9723,256,9722/17/2023
3.67126 % OrbiMed Advisors, LLC3,122,770012/31/2023
3.66443 % CPP Investment Board3,116,966012/31/2023
3.46556 % Adams Street Partners, LLC2,947,809012/31/2023
1
2
3
4
5
...
10

Fusion Pharmaceuticals Executives and Management Board

Dr. John Valliant53
Fusion Pharmaceuticals Chief Executive Officer, Founder, Director (since 2004)
Compensation 2.75 M
Mr. John Crowley49
Fusion Pharmaceuticals Chief Financial Officer
Compensation 1.44 M
Dr. Eric Burak58
Fusion Pharmaceuticals Chief Technology Officer (since 2021)
Compensation 1.42 M
Ms. Barbara Duncan58
Fusion Pharmaceuticals Independent Chairman of the Board
Compensation 118,949
Mr. Steven Gannon61
Fusion Pharmaceuticals Independent Director
Compensation 97,949
1
2
3

Fusion Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Roche Holding Stock
Roche Holding
SupplierCustomer0,660,95-0,41-0,39-0,43-0,68
Varian Medical Systems, Inc. Stock
Varian Medical Systems, Inc.
SupplierCustomer0,36-0,81-0,760,10--
ImmunoGen Stock
ImmunoGen
SupplierCustomer0,240,960,68-0,090,09-0,03
AstraZeneca Stock
AstraZeneca
SupplierCustomer-0,230,51-0,54-0,20-0,42-0,48
Cardinal Health Stock
Cardinal Health
SupplierCustomer-0,240,84-0,100,020,04-0,13
Merck & Co Stock
Merck & Co
SupplierCustomer-0,47-0,74-0,83-0,37-0,51-0,41
1

Most common questions regarding Fusion Pharmaceuticals

What values and corporate philosophy does Fusion Pharmaceuticals represent?

Fusion Pharmaceuticals Inc represents a commitment to advancing targeted alpha therapies to improve the lives of cancer patients. The company values innovation, collaboration, and scientific excellence in its pursuit of developing radiopharmaceuticals for the treatment of solid tumors. Fusion Pharmaceuticals believes in harnessing the power of precision medicine and next-generation radiopharmaceuticals to provide more effective and safer cancer therapies. With a focus on enhancing patient outcomes, Fusion Pharmaceuticals aims to revolutionize cancer treatment by delivering highly targeted radiation directly to tumor cells, minimizing damage to healthy tissues.

In which countries and regions is Fusion Pharmaceuticals primarily present?

Fusion Pharmaceuticals Inc is primarily present in various countries and regions across the globe. As a leading biopharmaceutical company, Fusion Pharmaceuticals Inc operates in key marketplaces such as the United States, Canada, Europe, and Asia. With its innovative radiopharmaceutical platform, Fusion Pharmaceuticals Inc aims to revolutionize the treatment of cancer by delivering targeted alpha-emitting radiopharmaceuticals. With its presence in multiple countries and regions, Fusion Pharmaceuticals Inc is dedicated to expanding access to its cutting-edge therapies worldwide and providing hope to patients suffering from cancer.

What significant milestones has the company Fusion Pharmaceuticals achieved?

Fusion Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) and began trading on the Nasdaq under the ticker symbol FUSN. Fusion Pharmaceuticals also secured strategic partnerships with various pharmaceutical companies, allowing them to advance their targeted alpha therapeutics. Additionally, the company received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, FPI-1434, for the treatment of solid tumors. Fusion Pharmaceuticals Inc continues to progress in its mission to develop next-generation radiopharmaceuticals for cancer treatment.

What is the history and background of the company Fusion Pharmaceuticals?

Fusion Pharmaceuticals Inc. is a biopharmaceutical company that specializes in targeted alpha therapies for the treatment of cancer. Founded in 2014, Fusion Pharma has rapidly emerged as a leader in the field, leveraging its innovative radiotherapeutics platform to develop novel treatments. The company combines alpha particle emitting isotopes with targeting molecules, enabling precise delivery of radiation directly to cancer cells while sparing healthy tissues. Fusion Pharma's mission is to revolutionize cancer therapy by developing highly effective and well-tolerated treatments that can improve patient outcomes. With a strong focus on research and development, Fusion Pharmaceuticals continues to advance its pipeline and explore new therapeutic opportunities to address unmet medical needs in oncology.

Who are the main competitors of Fusion Pharmaceuticals in the market?

The main competitors of Fusion Pharmaceuticals Inc in the market include Pfizer Inc., Novartis AG, Johnson & Johnson, and AstraZeneca PLC.

In which industries is Fusion Pharmaceuticals primarily active?

Fusion Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Fusion Pharmaceuticals?

The business model of Fusion Pharmaceuticals Inc. is focused on developing targeted alpha therapies (TAT) for the treatment of cancer. By utilizing its proprietary Targeted Alpha Therapeutics (TAT) platform, Fusion Pharmaceuticals aims to create highly specific radiotherapeutics that deliver alpha particle emitting isotopes directly to cancer cells while sparing healthy tissues. By selectively targeting cancer cells, Fusion Pharmaceuticals seeks to enhance the therapeutic potential and reduce associated toxicity of cancer treatments. Through its innovative TAT platform, Fusion Pharmaceuticals is dedicated to advancing the field of precision oncology and improving outcomes for patients with cancer.

What is the P/E ratio of Fusion Pharmaceuticals 2024?

The Fusion Pharmaceuticals P/E ratio is -11.26.

What is the P/S ratio of Fusion Pharmaceuticals 2024?

The Fusion Pharmaceuticals P/S ratio is 3,581.94.

What is the AlleAktien quality score of Fusion Pharmaceuticals?

The AlleAktien quality score for Fusion Pharmaceuticals is 2/10.

What is the revenue of Fusion Pharmaceuticals 2024?

The expected Fusion Pharmaceuticals revenue is 394,740 USD.

How high is the profit of Fusion Pharmaceuticals 2024?

The expected Fusion Pharmaceuticals profit is -125.61 M USD.

What is the business model of Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc is a biotechnology company specializing in the development of targeted radiation therapies for cancer. The company utilizes an innovative platform technology called bioorthogonal vectors (BOVs) to develop targeted alpha therapies (TAT). TAT is a novel approach in cancer treatment where a radioactive isotope is attached to a specific tumor-specific molecule, allowing the radioactive isotope to be delivered directly to the tumor while sparing the surrounding healthy tissue. Fusion Pharmaceuticals is currently involved in three business areas: TAT discovery and development, preclinical development, and clinical development. TAT discovery and development involve identifying target molecules and creating targeted molecules that bind to these targets. Preclinical development involves preparing the molecules for use in clinical trials. Clinical development involves conducting human studies to evaluate the safety and effectiveness of the product. The main product of Fusion Pharmaceuticals is currently FPX-01, a bovine serum albumin (BSA)-targeted TAT, which is currently being tested in clinical phase I/IIa in patients with advanced pancreatic and breast cancers. However, the company also plans to develop additional products that can treat various types of cancer. Another business area of Fusion Pharmaceuticals is collaborating with other companies to utilize the BOV technology in other applications. For example, the company has announced a collaboration agreement with AstraZeneca to use the BOV technology for targeted radiation therapy of tumors treated with AstraZeneca's immunotherapy products. Fusion Pharmaceuticals' business model relies on a combination of in-house research and development, collaborations with other companies, and raising capital through public offerings. The company has undergone several financing rounds in recent years to fund its research and development. Fusion Pharmaceuticals has also debuted on the NASDAQ stock exchange under the ticker symbol FUSN. Overall, Fusion Pharmaceuticals has garnered significant attention due to its innovative technology and promising clinical results, positioning itself to become a key player in cancer research. The BOV technology and TAT have the potential to revolutionize cancer treatment, and it remains to be seen what the future holds for Fusion Pharmaceuticals.

What is the Fusion Pharmaceuticals dividend?

Fusion Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Fusion Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Fusion Pharmaceuticals or the company does not pay out a dividend.

What is the Fusion Pharmaceuticals ISIN?

The ISIN of Fusion Pharmaceuticals is CA36118A1003.

What is the Fusion Pharmaceuticals ticker?

The ticker of Fusion Pharmaceuticals is FUSN.

How much dividend does Fusion Pharmaceuticals pay?

Over the past 12 months, Fusion Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Fusion Pharmaceuticals?

The current dividend yield of Fusion Pharmaceuticals is .

When does Fusion Pharmaceuticals pay dividends?

Fusion Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Pharmaceuticals?

Fusion Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Fusion Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Pharmaceuticals located?

Fusion Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Pharmaceuticals from 9/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Fusion Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Fusion Pharmaceuticals in the year 2023?

In the year 2023, Fusion Pharmaceuticals distributed 0 USD as dividends.

In which currency does Fusion Pharmaceuticals pay out the dividend?

The dividends of Fusion Pharmaceuticals are distributed in USD.

All fundamentals about Fusion Pharmaceuticals

Our stock analysis for Fusion Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.